MA38975A1 - Dispositif d'administration par voie intra-utérine - Google Patents

Dispositif d'administration par voie intra-utérine

Info

Publication number
MA38975A1
MA38975A1 MA38975A MA38975A MA38975A1 MA 38975 A1 MA38975 A1 MA 38975A1 MA 38975 A MA38975 A MA 38975A MA 38975 A MA38975 A MA 38975A MA 38975 A1 MA38975 A1 MA 38975A1
Authority
MA
Morocco
Prior art keywords
delivery device
intrauterine delivery
intrauterine
utérine
contraception
Prior art date
Application number
MA38975A
Other languages
English (en)
Inventor
Norbert Schmees
Katja Prelle
Bernhard Lindenthal
Ulrike Fuhrmann
Manja Ahola
Christine Talling
Lüder M Fels
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of MA38975A1 publication Critical patent/MA38975A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A61F6/142—Wirelike structures, e.g. loops, rings, spirals
    • A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne une méthode de contraception améliorée qui remédie aux problèmes posés par les saignements initiaux et les saignements vaginaux légers associés à l'utilisation de dispositifs d'administration par voie intra-utérine, ainsi qu'un dispositif d'administration par voie intra-utérine.
MA38975A 2013-10-21 2014-10-14 Dispositif d'administration par voie intra-utérine MA38975A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13397533 2013-10-21
PCT/EP2014/071990 WO2015055635A1 (fr) 2013-10-18 2014-10-14 Dispositif d'administration par voie intra-utérine

Publications (1)

Publication Number Publication Date
MA38975A1 true MA38975A1 (fr) 2017-11-30

Family

ID=49584678

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38975A MA38975A1 (fr) 2013-10-21 2014-10-14 Dispositif d'administration par voie intra-utérine

Country Status (19)

Country Link
US (1) US20160262923A1 (fr)
EP (1) EP3057573A1 (fr)
JP (1) JP2016539088A (fr)
KR (1) KR20160072114A (fr)
CN (1) CN105636577A (fr)
AU (1) AU2014336286A1 (fr)
CA (1) CA2927750A1 (fr)
CR (1) CR20160176A (fr)
CU (1) CU20160051A7 (fr)
DO (1) DOP2016000089A (fr)
IL (1) IL244508A0 (fr)
MA (1) MA38975A1 (fr)
MX (1) MX2016004930A (fr)
PE (1) PE20160534A1 (fr)
PH (1) PH12016500620A1 (fr)
SG (1) SG11201601688WA (fr)
TN (1) TN2016000134A1 (fr)
UY (1) UY35788A (fr)
WO (1) WO2015055635A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU201617347S (en) * 2016-12-23 2017-01-23 Jurox Pty Ltd intravaginal device
PE20211195A1 (es) * 2017-09-27 2021-07-01 Bayer Oy Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica
WO2021102220A1 (fr) 2019-11-21 2021-05-27 Coopersurgical, Inc. Systèmes d'emballage pour dispositifs implantables et procédés correpondants
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN112472975B (zh) * 2020-11-19 2022-04-12 华中科技大学 一种宫内药物控释系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI107339B (fi) * 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
KR20040036928A (ko) * 2001-08-31 2004-05-03 쉐링 오와이 약물 전달 시스템
DE10145269A1 (de) * 2001-09-14 2003-04-17 Siegfried R Riek Intrauterine Vorrichtung mit einem oder mehreren Pharmakadepots und integrierten Stellmitteln zur Variation der Abgabedosis
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
FI20085277A0 (fi) * 2008-04-02 2008-04-02 Bayer Schering Pharma Oy Kohdunsisäinen järjestelmä
EP2140860A1 (fr) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy Procédé de contraception amélioré

Also Published As

Publication number Publication date
UY35788A (es) 2015-05-29
SG11201601688WA (en) 2016-05-30
TN2016000134A1 (en) 2017-10-06
IL244508A0 (en) 2016-04-21
PH12016500620A1 (en) 2016-06-13
EP3057573A1 (fr) 2016-08-24
CA2927750A1 (fr) 2015-04-23
AU2014336286A1 (en) 2016-03-24
CN105636577A (zh) 2016-06-01
PE20160534A1 (es) 2016-06-15
CU20160051A7 (es) 2016-07-29
MX2016004930A (es) 2016-06-28
KR20160072114A (ko) 2016-06-22
US20160262923A1 (en) 2016-09-15
WO2015055635A1 (fr) 2015-04-23
DOP2016000089A (es) 2016-09-15
JP2016539088A (ja) 2016-12-15
CR20160176A (es) 2016-07-01

Similar Documents

Publication Publication Date Title
MA38975A1 (fr) Dispositif d'administration par voie intra-utérine
BR112015028722A2 (pt) interface de componente de sistema de detecção remota distribuída
EA201891055A1 (ru) Устройства для защиты от травматического повреждения головного мозга
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
AR095639A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario con el uso de un dispositivo móvil del usuario
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2016000158A (es) Dispositivo de oclusion con canal con posibilidad de apertura.
MX2020012800A (es) Cannabinoides y usos de los mismos.
EP3995091A4 (fr) Dispositif et système de curetage utérin à avortement à vision directe
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2015002785A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario
MX2018012250A (es) Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
CL2015003434A1 (es) Composición farmacéutica, su uso y régimen de administración para contracepción a demanda.
TR201907922T4 (tr) Düşük tehdidinin veya erken doğumun tedavisine veya önlenmesine yönelik lipoik asit.
EA201591892A1 (ru) Модуляторы прогестероновых рецепторов для применения в лечении фибромы матки
MX2014012849A (es) USO INTRAUTERINO DE 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-E N-3-ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, ASI COMO SU USO EN LA ANTICONCEPCION Y TERAPIA GINECOLOGICA.
MA53533A1 (fr) Conjugué persistant d'un triple activateur activant le récepteur du glucagon, du glp-1 et du gip
UA100789U (uk) Спосіб лікування пацієнток з аномальними матковими кровотечами на тлі антикоагуляційної терапії
AR098060A1 (es) Sistema de administración intrauterina
TR201708847A2 (tr) Ayakkabi i̇çi̇ dorsi̇fleksör
TWD196190S (zh) 出料裝置
UA112346C2 (uk) Спосіб поліпшення когнітивних функцій у породілей при кесаревому розтині
UY35789A (es) USO INTRAVAGINAL DE LAS 18-METIL-15ß, 16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, ANILLOS INTRAVAGIN ALES QUE COMPRENDEN 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS Y SU USO EN LA ANTICONCE PCIÓN